已核实 DOI PubMed 相关产品: 16

Gut microbiota-derived deoxycholic acid shapes an immunosuppressive tumor microenvironment and promotes breast cancer progression

Journal 2026 · IF 37 · 发表于 2026 年 5 月 12 日
作者: Lili Li,Chenghui Yang,Zhen Wang,Bangyi Zhou,Yixin Zhang,Huiying Liu,Shanshan Sun,Mengyao Chen,Xiaoxiao Hu,Fang Jia,Sangsang Zhu,Miner Shao,Jun Pan,Leyi Zhang,Xinyi Zhang,Shuyan Yuan,Jingxuan Zhu,I. Situ,Jian Huang,Fuming Qiu
阅读全文 在 PubMed 查看

摘要

The gut microbiota is increasingly recognized as a contributor to breast cancer progression. Here, we report that the gut bacterium Enterocloster bolteae , a member of the Lachnospiraceae family, is progressively enriched during tumor development and is associated with increased levels of the microbiota-derived metabolite deoxycholic acid. Deoxycholic acid accumulates in tumors and activates the farnesoid X receptor in tumor cells, inducing interleukin-6 production through nuclear factor κB signaling. Interleukin-6 promotes the recruitment of granulocytic myeloid-derived suppressor cells and T helper 17 cells, establishing an immunosuppressive microenvironment. Inhibition or knockdown of the farnesoid X receptor, as well as blockade of interleukin-6 signaling, attenuates these effects. These findings identify a microbiota-metabolite-immune axis driving breast cancer progression and uncover microbial metabolites as potential therapeutic targets.

本研究中使用的阿拉丁产品

16 款产品在本文中被引用